Sandra Grumelli1,2,3. 1. Centro de Investigaciones en Medicina Respiratoria, Universidad Católica de Córdoba, Cordoba, Argentina. 2. Pulmonary Division of the Brigham and Women's Hospital, Harvard Medical School, Boston, USA. 3. Departamento de Biologia Molecular, Universidad Nacional de Rio Cuarto, Rio Cuarto, Córdoba, Argentina.
Abstract
BACKGROUND: Although exacerbations of chronic obstructive pulmonary disease produced by Pseudomonas aeruginosa infections are a major cause of death, the molecular mechanism that produces them is not well known. Here we focused on the energetic basis of dyspnoea, hypercapnia and acidosis symptoms. METHODS AND FINDINGS: We used an in vivo exacerbation model exposing mice to cigarette smoke and LPS, to mimic emphysema and infections, and choline challenges to trigger exacerbations, that showed 31% increased in the airway resistance for naïve mice and 250% for smoke/LPS treatment. Tissue resistance was increased 32%, in naïve mice, and 169% for smoke/LPS treatment. A decreased tissue elastance, was confirmed by decreased collagen content and increased alveoli chord length. Consequently, the O2 demanded was 260% greater for smoke/LPS treated mice, to provide the energy required to pump the same volume of air then for naïve mice. The extra CO2 produced per ml of air pumped caused hypercapnia and acidosis by 4% decrease in pH.In addition, the bacteria grown with choline had a decrease of 67% in phosphate, 23% ATP and 85% phospholipids with an increase of 57% in polyphosphates, 50% carbohydrates, 100% LPS, consuming 45% less energy relative to the bacteria grown with succinate. CONCLUSION: choline, released by P. aeruginosa, triggers exacerbation symptoms by increasing lung resistance, O2 consumption and producing more pCO2 in blood with dyspnea, hypercapnia and acidosis. The energetic shift of decreased O2 bacterial demand and increased lung demand benefits the infection, thus restoring the energetic balance on the host will favor P. aeruginosa eradication.
BACKGROUND: Although exacerbations of chronic obstructive pulmonary disease produced by Pseudomonas aeruginosa infections are a major cause of death, the molecular mechanism that produces them is not well known. Here we focused on the energetic basis of dyspnoea, hypercapnia and acidosis symptoms. METHODS AND FINDINGS: We used an in vivo exacerbation model exposing mice to cigarette smoke and LPS, to mimic emphysema and infections, and choline challenges to trigger exacerbations, that showed 31% increased in the airway resistance for naïve mice and 250% for smoke/LPS treatment. Tissue resistance was increased 32%, in naïve mice, and 169% for smoke/LPS treatment. A decreased tissue elastance, was confirmed by decreased collagen content and increased alveoli chord length. Consequently, the O2 demanded was 260% greater for smoke/LPS treated mice, to provide the energy required to pump the same volume of air then for naïve mice. The extra CO2 produced per ml of air pumped caused hypercapnia and acidosis by 4% decrease in pH.In addition, the bacteria grown with choline had a decrease of 67% in phosphate, 23% ATP and 85% phospholipids with an increase of 57% in polyphosphates, 50% carbohydrates, 100% LPS, consuming 45% less energy relative to the bacteria grown with succinate. CONCLUSION: choline, released by P. aeruginosa, triggers exacerbation symptoms by increasing lung resistance, O2 consumption and producing more pCO2 in blood with dyspnea, hypercapnia and acidosis. The energetic shift of decreased O2 bacterial demand and increased lung demand benefits the infection, thus restoring the energetic balance on the host will favor P. aeruginosa eradication.
Authors: Timothy F Murphy; Aimee L Brauer; Karen Eschberger; Phyllis Lobbins; Lori Grove; Xueya Cai; Sanjay Sethi Journal: Am J Respir Crit Care Med Date: 2008-01-17 Impact factor: 21.405
Authors: Shyamala Ganesan; Andrea N Faris; Adam T Comstock; Sangbrita S Chattoraj; Asamanja Chattoraj; John R Burgess; Jeffrey L Curtis; Fernando J Martinez; Suzanna Zick; Marc B Hershenson; Uma S Sajjan Journal: Respir Res Date: 2010-09-28
Authors: Umadevi Sajjan; Shyamala Ganesan; Adam T Comstock; Jee Shim; Qiong Wang; Deepti R Nagarkar; Ying Zhao; Adam M Goldsmith; Joanne Sonstein; Marisa J Linn; Jeffrey L Curtis; Marc B Hershenson Journal: Am J Physiol Lung Cell Mol Physiol Date: 2009-09-11 Impact factor: 5.464
Authors: Karen Barnett; Stewart W Mercer; Michael Norbury; Graham Watt; Sally Wyke; Bruce Guthrie Journal: Lancet Date: 2012-05-10 Impact factor: 79.321
Authors: Beate Fuchs; Markus Rupp; Hossein A Ghofrani; Ralph T Schermuly; Werner Seeger; Friedrich Grimminger; Thomas Gudermann; Alexander Dietrich; Norbert Weissmann Journal: Respir Res Date: 2011-02-04